Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 25.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,111,111 shares of the biotechnology company's stock after buying an additional 2,222,223 shares during the period. Arrowhead Pharmaceuticals comprises about 3.0% of Avoro Capital Advisors LLC's holdings, making the stock its 13th largest position. Avoro Capital Advisors LLC owned approximately 8.88% of Arrowhead Pharmaceuticals worth $208,889,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. R Squared Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $38,000. Van ECK Associates Corp lifted its position in shares of Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after buying an additional 1,250 shares during the last quarter. KBC Group NV boosted its position in Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 1,644 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $205,000. Institutional investors own 62.61% of the company's stock.

Analyst Ratings Changes

ARWR has been the topic of a number of research analyst reports. Chardan Capital reissued a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. B. Riley restated a "buy" rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $41.44.

Arrowhead Pharmaceuticals Price Performance

ARWR stock traded up $0.33 during mid-day trading on Thursday, hitting $13.34. The company had a trading volume of 1,035,028 shares, compared to its average volume of 1,444,064. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41. The company has a 50-day moving average price of $14.72 and a 200 day moving average price of $18.43. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -2.58 and a beta of 0.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $11.49, for a total value of $583,692.00. Following the completion of the sale, the chief executive officer now directly owns 3,921,255 shares in the company, valued at $45,055,219.95. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold 275,880 shares of company stock valued at $4,034,037 in the last 90 days. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.